Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (5): 16-20.doi: 10.6040/j.issn.1671-7554.0.2024.0136

• Precision medicine in chronic airway diseases—Expert Overview • Previous Articles    

Research progress of mitochondrial damage-associated molecular patterns as biomarkers for chronic obstructive pulmonary disease

SHEN Yongchun1,2, WEN Fuqiang1,2   

  1. 1. Department of Pulmonary and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China;
    2. Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu 610041, Sichuan, China
  • Published:2024-05-29

PDF (PC)

45

Abstract: Chronic obstructive pulmonary disease(COPD)has high incidence rate, disability rate, mortality rate, and heavy economic burden, and it is a major disease burden that seriously affects the health of Chinese population. Finding reliable biomarkers for the diagnosis, evaluation, and prediction of mortality risk in COPD is currently a research hotspot. The mitochondrial damage-associated molecular patterns are closely related to COPD. Based on mitochondrial damage-associated molecular patterns, it is expected to find relevant biomarkers for COPD, providing further basis for the evaluation and treatment of COPD. This article reviews the research progress of the biomarker role of mitochondrial damage-associated molecular patterns for COPD.

Key words: Chronic obstructive pulmonary disease, Mitochondrial damage-associated molecular patterns, Biomarker

CLC Number: 

  • R562
[1] 王浩, 文富强. 2023年慢性阻塞性肺疾病全球倡议(GOLD)更新解读[J]. 中华结核和呼吸杂志, 2023, 46(5): 543-546. WANG Hao, WEN Fuqiang. Update and interpretation of global initiative for chronic obstructive pulmonary disease(GOLD)in 2023[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2023, 46(5): 543-546.
[2] Wang C, Xu JY, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
[3] Chen SM, Kuhn M, Prettner K, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study[J]. Lancet Glob Health, 2023, 11(8): e1183-e1193.
[4] 李薇, 杨汀, 王辰. 中国慢性阻塞性肺疾病防治现状及进展[J]. 中国研究型医院, 2020, 7(5): 1-5. LI Wei, YANG Ting, WANG Chen. Present situation and progress of prevention and treatment of chronic obstructive pulmonary disease in China[J]. Journal of Chinese Research Hospitals, 2020, 7(5): 1-5.
[5] Casaburi R, Celli B, Crapo J, et al. The COPD biomarker qualification consortium(CBQC)[J]. COPD, 2013, 10(3): 367-377.
[6] 蔡慧, 黄嘉楠, 金美玲. 慢性阻塞性肺疾病的生命组学研究进展[J]. 中华结核和呼吸杂志, 2019, 42(1): 45-49. CAI Hui, HUANG Jianan, JIN Meiling. Advances in bionomics of chronic obstructive pulmonary disease[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2019, 42(1): 45-49.
[7] 杨麟, 徐明, 贺蓓. 慢性阻塞性肺疾病生物标志物研究进展[J]. 中华结核和呼吸杂志, 2019, 42(4): 290-293. YANG Lin, XU Ming, HE Bei. Research progress on biomarkers of chronic obstructive pulmonary disease[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2019, 42(4): 290-293.
[8] Liu YB, Hong JR, Jiang N, et al. The role of mitochondrial quality control in chronic obstructive pulmonary disease[J]. Lab Invest, 2024, 104(2): 100307. doi:10.1016/j.labinv.2023.100307.
[9] 文富强, 申永春. 基于线粒体动力学的慢性阻塞性肺疾病发病机制与保护策略[J]. 西南医科大学学报, 2022, 45(5): 369-372. WEN Fuqiang, SHEN Yongchun. Pathogenesis and protective strategies of chronic obstructive pulmonary disease based on mitochondrial dynamics[J]. Journal of Southwest Medical University, 2022, 45(5): 369-372.
[10] 赵静, 万绍贵, 鲍登克. 线粒体损伤相关模式分子与宿主免疫调节[J]. 中国生物化学与分子生物学报, 2017, 33(1): 38-43. ZHAO Jing, WAN Shaogui, BAO Dengke. Mitochondrial damage-associated molecular patterns and immune regulation[J]. Chinese Journal of Biochemistry and Molecular Biology, 2017, 33(1): 38-43.
[11] Shen YC, Chen L, Chen J, et al. Mitochondrial damage-associated molecular patterns in chronic obstructive pulmonary disease: pathogenetic mechanism and therapeutic target[J]. J Transl Int Med, 2023, 11(4): 330-340.
[12] 甄宁新, 崔巍, 田宝平. 线粒体DNA激活cGAS-STING信号通路促进肺部炎性疾病的研究进展[J]. 中国病理生理杂志, 2022, 38(1): 144-153. ZHEN Ningxin, CUI Wei, TIAN Baoping. Progress of mitochondrial DNA promoting airway inflammatory diseases via cGAS-STING signaling pathway[J]. Chinese Journal of Pathophysiology, 2022, 38(1): 144-153.
[13] Li X, Wang T, Shen Y. The role of circulating mitochondrial DNA in modulating airway inflammation of chronic obstructive pulmonary disease [J]. Eur Respir J, 2014, 44(Suppl 58): P3858.
[14] Zhang WZ, Hoffman KL, Schiffer KT, et al. Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort[J]. Respir Res, 2021, 22(1): 126. doi:10.1186/s12931-021-01707-x.
[15] Zhang WZ, Rice MC, Hoffman KL, et al. Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort[J]. JCI Insight, 2020, 5(3): e133984. doi:10.1172/jci.insight.133984.
[16] Ware SA, Kliment CR, Giordano L, et al. Cell-free DNA levels associate with COPD exacerbations and mortality[J]. Respir Res, 2024, 25(1): 42. doi:10.1186/s12931-023-02658-1.
[17] Pelleg A, Schulman ES, Barnes PJ. Extracellular adenosine 5'-triphosphate in obstructive airway diseases[J]. Chest, 2016, 150(4): 908-915.
[18] Lommatzsch M, Cicko S, Müller T, et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2010, 181(9): 928-934.
[19] Hlap ci c I, Hulina-Tomaškovi c A, Somborac-Ba cura A, et al. Extracellular adenosine triphosphate is associated with airflow limitation severity and symptoms burden in patients with chronic obstructive pulmonary disease[J]. Sci Rep, 2019, 9(1): 15349. doi:10.1038/s41598-019-51855-w.
[20] Hlap ci c I, Belamari c D, Bosnar M, et al. Combination of systemic inflammatory biomarkers in assessment of chronic obstructive pulmonary disease: diagnostic performance and identification of networks and clusters[J]. Diagnostics, 2020, 10(12): 1029. doi:10.3390/diagnostics10121029.
[21] Zhang X, Li D, Wang H, et al. Elevated plasma cytochrome c levels in patients with chronic obstructive pulmonary disease [J]. Current Science, 2016, 10: 1532-1535. doi: 10.18520/cs/v110/i8/1532-1535.
[22] 张佑扬, 朱述阳, 朱洁晨, 等. 血清细胞色素C可作为慢性阻塞性肺疾病细胞损伤凋亡的生物标志物[J]. 临床肺科杂志, 2022, 27(11): 1696-1701. ZHANG Youyang, ZHU Shuyang, ZHU Jiechen, et al. Cytochrome C can be used as a biomarker of cellular damage and apoptosis in chronic obstructive pulmonary disease[J]. Journal of Clinical Pulmonary Medicine, 2022, 27(11): 1696-1701.
[23] 李孟颖, 王振刚, 刘爽, 等. 琥珀酸:对能量稳态调节具有多效功能的代谢物[J]. 生命科学, 2023, 35(9): 1128-1135. LI Mengying, WANG Zhengang, LIU Shuang, et al. Succinate: a pleiotropic metabolite in energy homeostasis[J]. Chinese Bulletin of Life Sciences, 2023, 35(9): 1128-1135.
[24] Wang C, Li JX, Tang D, et al. Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide-formoterol treatment[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 3511-3521. doi:10.2147/COPD.S152134.
[25] Sangiorgi C, Vallese D, Gnemmi I, et al. HSP60 activity on human bronchial epithelial cells[J]. Int J Immunopathol Pharmacol, 2017, 30(4): 333-340.
[26] Ou GC, Zhu MM, Huang YF, et al. HSP60 regulates the cigarette smoke-induced activation of TLR4-NF-κB-MyD88 signalling pathway and NLRP3 inflammasome[J]. Int Immunopharmacol, 2022, 103: 108445. doi:10.1016/j.intimp.2021.108445.
[27] An NE, An J, Zeng TT, et al. Research progress of mitochondria in chronic obstructive pulmonary disease: a bibliometric analysis based on the Web of Science Core Collection[J]. J Thorac Dis, 2024, 16(1): 215-230.
[1] CHEN Yingjun, LIU Tonggang. Comprehensive bioinformatics analysis to identify differentially expressed genes for aberrant methylation modification in HBV-associated HCC [J]. Journal of Shandong University (Health Sciences), 2023, 61(9): 101-117.
[2] LI Linlin, WANG Kai. Prediction of hepatocellular carcinoma prognostic genes based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 50-58.
[3] XIU Dejian, GAO Zhengwen, SONG Tingting, CUI Nan, CUI Jing, SUN Jianping. Genes associated with cervical cancer by integrated bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 99-109.
[4] KONG Xue, LI Juan, DUAN Weili, SHI Shuang, LI Peilong, DU Lutao, MAO Haiting, WANG Chuanxin. Effects of lncRNA AC012073.1 on the migration and invasion of human breast cancer cells and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 70-78.
[5] ZHANG Ning, YANG Yan, LI Rui, YIN Yunhong, LI Hao, QU Yiqing. Analysis of risk factors and drug resistance of Acinetobacter baumannii in patients with chronic obstructive pulmonary disease [J]. Journal of Shandong University (Health Sciences), 2019, 57(9): 88-96.
[6] YAN Suzhen, DU Lutao, WANG Lili, WANG Chuanxin. Expression and clinical significance of serum lncRNA UCA1 in esophageal squamous cell carcinoma [J]. Journal of Shandong University (Health Sciences), 2018, 56(6): 41-46.
[7] WANG Hongyang. Development of tumor biomarkers in the age of precision medicine [J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 1-2.
[8] WANG Chuanxin. Research progress of exosomes biomarkers in tumor development [J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 18-23.
[9] GAO Chunfang, HUANG Chenjun. Cancer biomarkers of intrahepatic cholangiocarcinoma and the clinical application [J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 24-30.
[10] PAN Shiyang. Research advances in markers for the evaluation of lung cancer efficacy [J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 31-39.
[11] YU Xiaolin, ZHANG Jun, YANG Liu, ZHOU Lin, CUI Liangliang, ZHANG Ji. Epidemiological characteristics of COPD patients attacked by respiratory system diseases during the flu season in Jinan City [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 79-82.
[12] GU Jianhua, MA Xiaotian, LI Jiqing, XUE Fuzhong, WANG Jialin. Risk prediction model of chronic obstructive pulmonary disease in health management cohort [J]. Journal of Shandong University (Health Sciences), 2017, 55(12): 62-65.
[13] DU Yifeng, JING Ran. Diagnosis and treatment of Alzheimers disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 7-13.
[14] TANG Yi. Evolution of diagnostic criteria for Alzheimers disease: from clinical diagnosis to pathophysiological diagnosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 14-20.
[15] PAN Qing, LÜ Zhifang. Clinical application value of the new guide for patients with chronic obstructive pulmonary disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 63-67.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd